Enzymes

Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting GLP-1 ( glucagon-like peptide-1) receptor agonist that promotes insluin secretion, and of potential use in the treatment of MASH.

Lixisenatide is a GLP-1 (glucagon-like peptide-1) receptor agonist used in the treatment of type 2 diabetes (T2D). Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways.

Lixisenatide is a GLP-1 (glucagon-like peptide-1) receptor agonist used in the treatment of type 2 diabetes (T2D). Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide is used in the treatment of type 2 diabetes (T2D) and obesity.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide is used in the treatment of type 2 diabetes (T2D) and obesity.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide is used in the treatment of type 2 diabetes (T2D) and obesity.

Recombinant human complex made of USP1 (ubiquitin specific peptidase 1), encompassing amino acids 2-785(end), and UAF1 (ubiquitin specific peptidase 1), encompassing amino acids 1-677 (end). The USP1 construct contains an N-terminal FLAG-Tag and the UAF1 construct contains a C-terminal His-tag (6xHis). The proteins were co-expressed and purified as a complex. Two mutations of interest are present in USP1, G670A, G671A.